Dave is a biotech entrepreneur with nearly 20 years of drug development and leadership experience in small biotech companies. A microbiologist and immunologist by training, Dave has served as the Chief Scientific Officer in multiple early to mid-stage biotech companies where he has built and led dynamic and innovative Research and Development organizations and advanced numerous programs from discovery to late-stage clinical development.
Prior to joining Mass General Brigham, he was the Chief Scientific Officer and Head of Research and Development at Synlogic, where he led the discovery and development of first-in-class therapies using synthetic biology to engineer and program bacteria as living medicines. In previous roles Dave was the Chief Scientific Officer at Pulmatrix and Metera Pharmaceuticals, companies developing inhaled therapies for serious respiratory disease, having joined both companies prior to Series A fundraising.
He earned his Ph.D. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training studying immunology and host-pathogen interactions at Brigham and Women’s Hospital and Harvard Medical School. As a post-doctoral fellow, Dave was awarded a Damon Runyan Cancer Research Fellowship. He has co-authored numerous manuscripts and abstracts focused on synthetic biology, immunology, autoimmunity, rare disease and platform development.